Headlands Technologies LLC Takes $173,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Headlands Technologies LLC purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,092 shares of the company’s stock, valued at approximately $173,000.

Several other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC increased its stake in shares of Recursion Pharmaceuticals by 52.6% during the second quarter. Quest Partners LLC now owns 24,219 shares of the company’s stock valued at $182,000 after buying an additional 8,351 shares during the period. Pier 88 Investment Partners LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at $185,000. Mosley Wealth Management purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at $111,000. Los Angeles Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at $246,000. Finally, Arizona State Retirement System increased its stake in shares of Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock valued at $358,000 after buying an additional 4,760 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on RXRX shares. Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.40.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now directly owns 7,177,116 shares of the company’s stock, valued at $68,254,373.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now directly owns 7,177,116 shares of the company’s stock, valued at $68,254,373.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total value of $92,550.00. Following the completion of the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at $8,500,754.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 231,682 shares of company stock valued at $1,663,867. 15.75% of the stock is owned by company insiders.

Recursion Pharmaceuticals Trading Up 1.1 %

Recursion Pharmaceuticals stock opened at $6.57 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.97 and a 52 week high of $15.74. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -4.11 and a beta of 0.82. The stock has a 50-day moving average price of $7.23 and a 200 day moving average price of $8.55.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same period last year, the firm earned ($0.38) EPS. The company’s revenue for the quarter was up 30.9% compared to the same quarter last year. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.